Abionyx Pharma
33-43 Avenue Georges Pompidou, Bâtiment D2, Balma, Midi-Pyrenees, 31130, France
Overview
Abionyx Pharma is a biotech company based in Balma developing therapies to combat sepsis, with its lead investigational candidate CER-001 aimed at treating septic shock. The company has launched an €18.7M capital increase with preferential subscription rights and secured a subscription agreement with Fenja Capital for up to €14M in two tranches. Those financings provide immediate funding of €28.7M and could total €32.7M if the second tranche is exercised. Abionyx says the proceeds will be used to accelerate development of CER-001. No prior funding rounds or operating metrics were disclosed in the article.
- Total raised
- $78M
- Funding rounds
- 4
- Latest round
- Equity
- Latest activity
- Dec 2025
Industries
- Biotechnology
- Health Care
Recent funding
Equity
Dec 2025
$2M
Grant
Feb 2025
$10M
Series C
Oct 2010
$14M
Series C
Jul 2010
$52M